To help unbiasedly assess the potential roles of SWI/SNF genes in modulating cisplatin responses, we performed a pooled CRISPR knockout screen targeting 496 epigenetic modifiers in OVCAR4, a SMARCA4/2-proficient high-grade serous ovarian carcinoma (HGSC) cell line (Fig. 1c). This evidence concerns the gene SMARCA4 and ovarian serous carcinoma.